Patents by Inventor F. Carter Bancroft

F. Carter Bancroft has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6586581
    Abstract: The present invention relates to isolated nucleic acid molecules encoding Prolactin Regulatory Element Binding protein (PREB) and recombinant proteins encoded thereby. The nucleic acid sequences are useful in the production of recombinant PREB, as probes, and in the control of gene expression, and in particular, in the control of prolactin gene expression. In particular embodiments of the invention, PREB nucleic acid sequences are used to detect transcripts of the gene in astrocytomas, to detect trisomy and to detect a propensity of a subject to develop osteoporosis. In other embodiments of the invention, the PREB nucleic acid sequences, or the products thereof, are used for preventing or controlling osteoporosis in a subject.
    Type: Grant
    Filed: March 23, 2000
    Date of Patent: July 1, 2003
    Assignee: The Mt. Sinai School of Medicine of New York University
    Inventors: F. Carter Bancroft, Maikiko Fliss, Catherine L. Clelland
  • Patent number: 4677054
    Abstract: A simple technique for the simultaneous measurement of relative levels of a specific mRNA in numberous small samples of biological specimens is described. The technique involves denaturation of cytoplasmic preparations, followed by dotting of up to 96 samples onto a single sheet of nitrocellulose, hybridization with a .sup.32 P-labeled cDNA plasmid, autoradiography, and scanning. By analyzing cytoplasmic preparations instead of purified RNA, manipulations of multiple samples prior to analysis are minimized. Experiments with a clonal line of rat pituitary tumor (GH.sub.3) cells show that this technique can be employed to follow the induction by Ca.sup.2+ of prolactin mRNA sequences, employing cytoplasm prepared from as little as 2.5.times.10.sup.4 cells. The specificity of the technique for prolactin mRNA is shown by employing GC cells, a GH.sub.3 cell variant lacking detectable prolactin mRNA sequences.
    Type: Grant
    Filed: August 8, 1983
    Date of Patent: June 30, 1987
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Bruce A. White, F. Carter Bancroft